Literature DB >> 27957055

Management of Atrial Fibrillation in Patients With Kidney Disease.

Yee C Lau1, Gregory Y H Lip1.   

Abstract

The increasing burden of Chronic Kidney Disease (CKD) is highly relevant to cardiologists, as cardiovascular mortality is 10-30 times higher amongst people with End-stage Renal Disease (ESRD), comparing with general population. One of the commonest associations is the increased frequency of atrial fibrillation (AF) amongst those experiencing CKD. Overall, we know that AF is the most common cardiac arrhythmia. AF leads to a substantial risk of mortality and morbidity, from stroke and thromboembolism, heart failure, reduced cognitive function and impaired quality of life. However, most clinical trials in AF (for example, for stroke prevention in AF with anticoagulation therapy) have largely excluded patients with significant renal impairment. In this review article, we will focus on stroke prevention in AF, and the clinical impact of CKD and its implications for management.

Entities:  

Keywords:  Anticoagulation; Atrial Fibrillation; Chronic Kidney disease; Stroke Prevention

Year:  2014        PMID: 27957055      PMCID: PMC5135232          DOI: 10.4022/jafib.989

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  78 in total

1.  Clinical characteristics associated to atrial fibrillation in chronic hemodialysis patients.

Authors:  F Fabbian; C Catalano; D Lambertini; G Tarroni; V Bordin; R Squerzanti; P Gilli; D Di Landro; R Cavagna
Journal:  Clin Nephrol       Date:  2000-09       Impact factor: 0.975

2.  Chronic kidney disease and end-stage renal disease predict higher risk of mortality in patients with primary upper gastrointestinal bleeding.

Authors:  Puneet Sood; Gagan Kumar; Rahul Nanchal; Ankit Sakhuja; Shahryar Ahmad; Muhammad Ali; Nilay Kumar; Edward A Ross
Journal:  Am J Nephrol       Date:  2012-02-04       Impact factor: 3.754

Review 3.  Chronic kidney disease-mineral-bone disorder: a new paradigm.

Authors:  Sharon M Moe; Tilman Drüeke; Norbert Lameire; Garabed Eknoyan
Journal:  Adv Chronic Kidney Dis       Date:  2007-01       Impact factor: 3.620

4.  Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.

Authors:  Amitava Banerjee; Deirdre A Lane; Christian Torp-Pedersen; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2011-12-21       Impact factor: 5.249

5.  Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD.

Authors:  Juan Jesús Carrero; John Kyriazis; Alper Sonmez; Ioannis Tzanakis; Abdul Rashid Qureshi; Peter Stenvinkel; Mutlu Saglam; Kostas Stylianou; Halil Yaman; Abdullah Taslipinar; Abdulgaffar Vural; Mahmut Gok; Mujdat Yenicesu; Eugene Daphnis; Mahmut Ilker Yilmaz
Journal:  Clin J Am Soc Nephrol       Date:  2011-12-22       Impact factor: 8.237

6.  Tissue factor coagulation pathway and blood cells activation state in renal insufficiency.

Authors:  E Mercier; B Branger; F Vecina; B Al-Sabadani; J Berlan; M Dauzat; J Fourcade; J C Gris
Journal:  Hematol J       Date:  2001

7.  Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation.

Authors:  Pilar Gallego; Vanessa Roldan; Francisco Marín; Marta Romera; Mariano Valdés; Vicente Vicente; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2013-10-07       Impact factor: 5.249

8.  Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS.

Authors:  Manish M Sood; Maria Larkina; Jyothi R Thumma; Francesca Tentori; Brenda W Gillespie; Shunichi Fukuhara; David C Mendelssohn; Kevin Chan; Patricia de Sequera; Paul Komenda; Claudio Rigatto; Bruce M Robinson
Journal:  Kidney Int       Date:  2013-05-15       Impact factor: 10.612

9.  Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?

Authors:  V Roldán; F Marín; S Manzano-Fernandez; H Fernández; P Gallego; M Valdés; V Vicente; G Y H Lip
Journal:  Thromb Haemost       Date:  2013-03-21       Impact factor: 5.249

10.  Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation.

Authors:  Yutao Guo; Haijun Wang; Xiaoning Zhao; Yu Zhang; Dexian Zhang; Jingling Ma; Yutang Wang; Gregory Y H Lip
Journal:  Int J Cardiol       Date:  2013-07-30       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.